Novo Nordisk Faces FDA Notice Over Ozempic Advertisement

Novo Nordisk has received a notice from the U.S. Food and Drug Administration (FDA) regarding its advertisement for the diabetes medication Ozempic. Bloomberg posted on X that this comes shortly after the FDA criticized a TV ad for Novo Nordisk's weight-loss drug Wegovy, citing 'false or misleading' claims. The FDA's recent action highlights ongoing scrutiny of pharmaceutical advertising practices. Novo Nordisk has not yet commented on the notice concerning Ozempic. The company is known for its significant presence in the diabetes and weight management sectors.